Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors

Clinical trial NCT03905148 · COMPLETED

Trial details

NCT number: NCT03905148
Sponsor: BeiGene
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Solid Tumor, Adult

Start date: 2019-05-01
Primary completion: 2024-10-09
Enrollment: 91

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.